Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2024 Nov 5;21(11):e1004448. doi: 10.1371/journal.pmed.1004448

Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950–1963: An epidemiological analysis of historical data

Peter MacPherson 1,2,3,*, Helen R Stagg 4, Alvaro Schwalb 4,5, Hazel Henderson 3, Alice E Taylor 3, Rachael M Burke 2, Hannah M Rickman 2,6, Cecily Miller 7, Rein M G J Houben 4, Peter J Dodd 8,#, Elizabeth L Corbett 2,#
Editor: Amitabh Bipin Suthar9
PMCID: PMC11537369  PMID: 39499677

Abstract

Background

Community active case finding (ACF) for tuberculosis was widely implemented in Europe and North America between 1940 and 1970, when incidence was comparable to many present-day high-burden countries. Using an interrupted time series analysis, we analysed the effect of the 1957 Glasgow mass chest X-ray campaign to inform contemporary approaches to screening.

Methods and findings

Case notifications for 1950 to 1963 were extracted from public health records and linked to demographic data. We fitted Bayesian multilevel regression models to estimate annual relative case notification rates (CNRs) during and after a mass screening intervention implemented over 5 weeks in 1957 compared to the counterfactual scenario where the intervention had not occurred. We additionally estimated case detection ratios and incidence. From 11 March 1957 to 12 April 1957, 714,915 people (622,349 of 819,301 [76.0%] resident adults ≥15 years) were screened with miniature chest X-ray; 2,369 (0.4%) were diagnosed with tuberculosis. Pre-intervention (1950 to 1956), pulmonary CNRs were declining at 2.3% per year from a CNR of 222/100,000 in 1950. With the intervention in 1957, there was a doubling in the pulmonary CNR (RR: 1.95, 95% uncertainty interval [UI] [1.81, 2.11]) and 35% decline in the year after (RR: 0.65, 95% UI [0.59, 0.71]). Post-intervention (1958 to 1963) annual rates of decline (5.4% per year) were greater (RR: 0.77, 95% UI [0.69, 0.85]), and there were an estimated 4,599 (95% UI [3,641, 5,683]) pulmonary case notifications averted due to the intervention. Effects were consistent across all city wards and notifications declined in young children (0 to 5 years) with the intervention. Limitations include the lack of data in historical reports on microbiological testing for tuberculosis, and uncertainty in contributory effects of other contemporaneous interventions including slum clearances, introduction of BCG vaccination programmes, and the ending of postwar food rationing.

Conclusions

A single, rapid round of mass screening with chest X-ray (probably the largest ever conducted) likely resulted in a major and sustained reduction in tuberculosis case notifications. Synthesis of evidence from other historical tuberculosis screening programmes is needed to confirm findings from Glasgow and to provide insights into ongoing efforts to successfully implement ACF interventions in today’s high tuberculosis burden countries and with new screening tools and technologies.


Peter MacPherson and colleagues analyze public health records and demographics data using an interrupted time series approach to explore the effect of the 1957 Glasgow mass chest X-ray campaign for tuberculosis case finding.

Author summary

Why was this study done?

  • Tuberculosis screening is conditionally recommended by the World Health Organization for populations with a high prevalence of disease or other structural risk factors.

  • There is considerable uncertainty over the optimal approaches and population impact of tuberculosis screening.

  • Between 1930 and 1970, mass screening for tuberculosis was widely undertaken, in Europe and North America, but there has been little attempt to understand what effect these programmes had on the trajectory of tuberculosis epidemics.

What did the researchers do and find?

  • Over a 5-week period, in 1957, the city of Glasgow, Scotland implemented a tuberculosis screening programme comprising mass miniature X-ray of around 715,000 people supported by community mobilisation.

  • Tuberculosis notification data and population demographics were extracted from city Medical Officer of Health reports between 1950 and 1963, and multilevel interrupted time series regression models were constructed to investigate the effect of the mass screening campaign on tuberculosis notifications, compared to the counterfactual scenario where the intervention had not occurred.

  • Before the mass screening intervention (1950 to 1956), tuberculosis notification rates were declining at 2.3% per year, and rates doubled in the year of the intervention (1957). Post-intervention, tuberculosis notification rates declined at 5.4% per year, and there were an estimated 4,599 pulmonary notifications averted.

  • Intervention effects were consistent across all 37 city wards, but showed differing effects by age group and sex.

What do these findings mean?

  • A single, rapid, and high coverage round of mass tuberculosis screening, supported by intensive community mobilisation, likely had a major impact on changing the tuberculosis epidemiology trajectory in Glasgow.

  • Greater understanding of how improved housing, social conditions, and tuberculosis care and prevention contributed to this screening effect is needed.

  • Synthesis of evidence from other historical tuberculosis screening programmes is needed to confirm findings from Glasgow, and to support efforts to successfully implement active case finding (ACF) interventions in today’s high tuberculosis burden countries and with new screening tools and technologies.

Introduction

Tuberculosis has been a scourge of humankind for millennia [1]. From the late 18th to the early 20th centuries, improvements in housing, nutrition, and air quality [2]—as well as progressive improvements in tuberculosis care, treatment, and prevention [3]—yielded substantial reductions in incidence and mortality in countries such as the United Kingdom [4].

By the 1940s, it was recognised that additional measures would be required to stem the source of Mycobacterium tuberculosis infections and prevent tuberculosis disease [5]. In line with other European and American cities in the 1940 to 1960s [6], Scotland implemented active case finding (ACF) in communities through mass chest X-ray screening campaigns [7]. To our knowledge, the largest single site tuberculosis ACF intervention ever implemented globally was in Glasgow, Scotland, in 1957 [6]. By the end of the Second World War, Glasgow had extremely high levels of social deprivation and nearly one out of every thousand people resident in Glasgow died of pulmonary tuberculosis annually [8]. Whereas incidence of tuberculosis and mortality had declined substantially in other major UK cities, progress in Glasgow had lagged considerably behind [9].

In 1974, the World Health Organization (WHO) recommended “the policy of indiscriminate tuberculosis case finding by mobile mass radiography should now be abandoned” due to the declining diagnostic yield from screening programmes [10]. Yet, currently many countries in Africa and Asia have tuberculosis epidemiological indicators similar to those of Europe and North America in the 1940s and 1950s [11]. This suggests that the experiences of ACF in cities like Glasgow are highly informative for the modern day. Indeed, the WHO made a conditional recommendation in favour of ACF for communities where the prevalence of undiagnosed pulmonary tuberculosis was >1,000 per 100,000 in 2013 [12], lowering this threshold to a prevalence of >500 per 100,000 in 2021 [13].

Action is needed to implement high-impact interventions that can change the trajectory of tuberculosis epidemics in high-burden nations. Despite renewal of interest in ACF [14]—and more recent trial evidence [15,16]—there remains considerable uncertainty over how and where ACF should be implemented, and what effects can be expected to be achieved [17]. Using comprehensive historical records, we therefore set out to estimate the impact of the 1957 Glasgow mass tuberculosis screening intervention to inform contemporary approaches to ACF in high tuberculosis burden countries.

Methods

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).

Mass miniature X-ray screening intervention

The Glasgow mass X-ray campaign was coordinated by the Corporation of Glasgow, the Western Regional Hospital Board, the Scottish Information Office, and the Department of Health for Scotland, and mass miniature X-ray screening took place between the 11th of March and 12th April 1957 [18]. A total of 37 mobile miniature X-ray units with radiographers were seconded from cities across the UK, and the campaign was supported by approximately 12,000 Glasgow volunteers. Across the city, screening activities were divided into 6 sections that aligned with 5 geographical city divisions plus a further section focused on activities within the city centre and business area.

Prior to the campaign substantial publicity and public engagement was undertaken, including: house-to-house visits within each city ward to distribute X-ray invitation cards; press and cinema advertising; poster displays; church services; distribution of leaflets, banners and stickers; loudspeaker vans and an illuminated tramcart; pavement stencils; aeroplane banner advertising; 2 specially commissioned campaign songs that were played on the radio and at football matches; and information printed on municipal letterheads.

All people who underwent chest X-ray received a badge, and randomly selected people wearing badges within Divisions received small gifts such as chocolates, chickens, and cigarettes. During each week of the campaign, larger gifts (refrigerators, televisions, washing machines, holidays, furniture, and a car) were distributed by selecting X-ray cards at random, and the 100,000th, 200,000th, and 250,000th person X-rayed received additional gifts.

X-ray units were situated in department stores, churches, schools, and other municipal buildings. People aged 15 years or older were invited to receive chest X-ray, regardless of the presence or absence of symptoms, with miniature films interpreted by medical officers. Where there was “significant radiological abnormality requiring further investigation or supervision,” people were recalled for a large film at a central X-ray site, and assessment/further investigation by physicians at 5 city hospitals chest clinics (1 per Division, including microbiological testing of sputum) and tuberculosis treatment (if required).

Setting and population

For this analysis, we used the municipal boundaries of Glasgow City as defined in 1951. Wards are electoral boundaries used in UK national parliamentary elections, and Glasgow City was divided into 37 wards within 5 divisions (North, East, Central, South-East, and South-West). To obtain spatial boundaries, we digitised a scale 1951 Post Office Directory map held in the City of Glasgow Archives using QGIS software (S1 Fig).

We extracted overall city and ward-specific annual population estimates as reported in Medical Officer of Health reports for Glasgow between 1950 and 1963 [19]. In reports, population estimates were based on national censuses (1951 and 1961), updated annually by the Medical Officer of Health based on linear projections of ratios of census populations to registered voters. For this analysis, we used 2 population denominators available: (a) total population (all people identified as usually resident within the City of Glasgow, including people in long-term institutional care and sailors stationed on ships of the Royal Navy at sea or in ports abroad); and (b) the population excluding people in institutional care or shipping. In reports, population denominators were adjusted for each year to account for city-wide and ward-specific trends. Population estimates stratified by age and sex were not available for each ward.

Tuberculosis notifications

For each year between 1950 and 1963, we extracted from annual Medical Officer of Health Reports for the City of Glasgow [19] overall numbers of tuberculosis notifications (stratified by pulmonary and extra-pulmonary status, and separately by age group and sex) and the ward-specific notifications (stratified by pulmonary and extra-pulmonary status, and sex). In 1962 and 1963, extra-pulmonary cases were not reported by ward due to small numbers.

Statistical methods

We calculated the annual pulmonary and extra-pulmonary tuberculosis case notification rate (CNR) for the City of Glasgow using overall numbers of notifications and the total population denominator and scaled these data per 100,000 people. We additionally calculated the ward-specific pulmonary and extrapulmonary CNRs using the population excluding people in institutional care or shipping as the denominator, as cases occurring among institutionalised people or in shipping were not allocated to wards.

To investigate the impact of the 1957 ACF intervention, we constructed multi-level Bayesian interrupted time series regression models (S1 Text) to estimate annual pulmonary tuberculosis CNRs and extra-pulmonary tuberculosis notification rates. Models included terms for a “level-change” in 1957 to capture the immediate effect of the intervention and a “slope change” to estimate changing rates before and after the intervention. To account for over-dispersion, we used the negative binomial distributional family; priors were weakly informative and assessed by inspecting plots of joint prior distributions. Models were fit using the “brms” interface to Stan in R [20], and model convergence was assessed using R^ statistics, effective sample size measures, trace plots of chains, and posterior predictive plots comparing observed data to simulated data from the empirical cumulative distribution function.

We drew 4,000 samples from model posteriors and summarised these (using means and quantile-based 95% uncertainty intervals [UI]). To investigate the impact of the ACF intervention overall and by ward, we predicted counterfactual CNRs for 1958 to 1963 based on a linear projection of trends from the pre-ACF period (1950 to 1956) under the scenario where the ACF intervention had not happened. We then estimated: (i) the relative CNR in 1957 compared to the counterfactual for the same year (“peak effect”); (ii) the “level effect” (relative rate in 1958 versus counterfactual for 1958); and (iii) the “slope effect” (relative annual change in case notifications in 1958 to 1963 compared to the counterfactual scenario). Pairwise correlations between posterior draws for the peak effect, step effect, and slope effect were plotted by ward. Using model predictions, we calculated the number of tuberculosis case notifications that were averted in the post-ACF period (1958 to 1963) compared to that predicted by the counterfactual scenario. We additionally investigated whether the impact of the ACF intervention differed by age and sex by fitting a model to estimate the annual counts of pulmonary tuberculosis case notifications using a Poisson distribution and summarised as above. All analysis was conducted using R version 4.2.3 (R Core Team, Vienna).

Estimates of case detection and incidence

We estimated the incidence and case detection ratio (CDR; percentage of estimated new pulmonary tuberculosis cases notified annually) for each ward using an equilibrium competing hazards model and the assumption that the excess notified cases (Nduring−Npre) were prevalent during the intervention and detected with a coverage (cov) taken to be 76% based on screening uptake (S2 Text).

odds(CDR)=T×cov(R1)

Here, R=Nduring/Npre is the ratio of notification rates during versus before the intervention, T is the average duration of tuberculosis disease in the absence of detection and treatment, taken to be 3 years [21]. We examined the empirical correlations across wards between CDR, pre-ACF incidence, and ACF impact quantified as relative decrease in notifications pre/post-ACF.

Ethical statement and data availability

Ethical approval was not required for this analysis. Data and code to reproduce analysis are available at https://github.com/petermacp/glasgow-cxr.

Results

Population

The total population of Glasgow City was 1.1 million in 1950, declining to just over 1 million by 1963 (Table 1). Ward populations ranged from 16,321 people (Knightswood) to 44,595 (Dalmarnock) in 1950. There was considerable variation in the change in population by 1963, with some wards having substantial population increases (Provan: +312%), and others declining (Exchange: −57%) (S2 Fig). Between 1950 and 1963, we included a total of 14,649,693 person-years of follow-up (population excluding people in institutional care or shipping) in regression models.

Table 1. Population and tuberculosis notifications in Glasgow City, 1950–1963.

Year Total estimated population* Pulmonary tuberculosis notifications Pulmonary tuberculosis case notification rate (per 100,000) Extra-pulmonary tuberculosis notifications Extra-pulmonary tuberculosis notification rate (per 100,000) Total tuberculosis notifications Total tuberculosis case notification rate (per 100,000) Percent of tuberculosis notifications that were pulmonary
1950 1,100,000 2,446 222.4 369 33.5 2,815 255.9 86.9%
1951 1,089,767 2,207 202.5 355 32.6 2,562 235.1 86.1%
1952 1,086,800 2,264 208.3 301 27.7 2,565 236.0 88.3%
1953 1,085,000 2,368 218.2 295 27.2 2,663 245.4 88.9%
1954 1,084,700 2,201 202.9 241 22.2 2,442 225.1 90.1%
1955 1,085,100 2,181 201.0 278 25.6 2,459 226.6 88.7%
1956 1,083,500 2,024 186.8 193 17.8 2,217 204.6 91.3%
1957 1,079,800 3,925 363.5 172 15.9 4,097 379.4 95.8%
1958 1,078,400 1,340 124.3 167 15.5 1,507 139.7 88.9%
1959 1,075,800 1,159 107.7 120 11.2 1,279 118.9 90.6%
1960 1,064,700 1,092 102.6 109 10.2 1,201 112.8 90.9%
1961 1,053,100 1,021 97.0 137 13.0 1,158 110.0 88.2%
1962 1,044,500 927 88.8 117 11.2 1,044 100.0 88.8%
1963 1,029,147 863 83.9 116 11.3 979 95.1 88.2%

*Total populations and case notifications, including those in institutional care and shipping.

Mass miniature X-ray campaign in 1957.

Across each year in Glasgow City, there was a greater number of females than males, with the sex ratio slightly declining from 1:1.10 in 1950 to 1.08 in 1963. The difference in population sex ratio was driven by fewer men compared to women aged 45 years or older (S3 Fig).

The Glasgow mass miniature chest X-ray campaign

Between 11 March and 12 April 1957, a total of 714,915 people underwent miniature chest X-ray in the campaign. Of these, 19,466 (2.7%) were <15 years, and 73,100 (10.2%) were not resident in Glasgow, leaving 622,349 adult Glasgow-resident participants, 76.0% of the estimated 819,301 adult resident population. A greater percentage of female adult residents (340,474/437,588, 77.8%) than male adult residents (281,875/381,713, 73.8%) underwent chest X-ray, and uptake was highest in younger age groups (S4 Fig). A total of 30,506 people (4.3% of all X-rayed) were recalled for full film, with 652, (2.1%) not attending; 13,900 (45.6%) were subsequently assessed at chest clinics. In total, 2,565 participants were diagnosed as having new active tuberculosis requiring treatment, with 33 of these <15 years and 196 nonresident, resulting in 2,369/622,349 (0.4%) adult Glasgow resident cases detected; approximately 65% were treated as outpatients. A further 1,556 people of all ages were notified with tuberculosis through routine systems during 1957, meaning that the ACF campaign accounted for 60% of all notifications in that year. Of the 2,369 adult Glasgow residents diagnosed with tuberculosis due to screening, 58.5% (1,387) were male, and prevalence was highest in older age groups; 523 (22%) were bacteriologically confirmed by isolation of M. tuberculosis. In the year of the campaign, tuberculosis notifications were lower in young children (0 to 5 years) compared to the years before, and a greater percentage of tuberculosis cases were in older age groups; this was maintained in the post-ACF period (S5 Fig). A substantial burden of other disease was identified through the miniature chest X-ray campaign, including lung cancer (n = 327), pulmonary fibrosis (n = 1,279), and cardiac abnormalities (n = 1,072).

Tuberculosis case notifications prior to active case finding intervention

In 1950, a total of 2,815 people were notified with tuberculosis in Glasgow City, giving a CNR of 255.9 per 100,000. Of these 87% were pulmonary notifications (n = 2,446, CNR: 222.4 per 100,000), and 13% were extra-pulmonary (n = 369, CNR: 33.5 per 100,000). Pulmonary tuberculosis case notifications rates varied by ward, with the highest CNR in 1950 in Provan (68/19,297, 352.4 per 100,000) and the lowest in Camphill (16/23,630, 67.8 per 100,000)—Fig 1.

Fig 1. Pulmonary tuberculosis CNRs in Glasgow City, 1950–1963.

Fig 1

(A) Pulmonary tuberculosis CNRs (per 100,000 population) by Glasgow City ward. Ward boundaries obtained from a scale 1951–1952 Post Office Directory map drawn by John Bartholomew FRSG held within the City of Glasgow Archive Special Collections (item PSI-52), digitalised using QGIS 3.34.1. Ward names can be seen in S1 Fig. (B) Empirical (points) and modelled (pink and blue bands) pulmonary tuberculosis CNRs (per 100,000 population), with counterfactual of no ACF intervention (grey bands). The mass miniature X-ray active case finding campaign occurred between dashed lines (11 March–12 April 1957). Points are empirical data based on total population estimates and numbers of pulmonary tuberculosis notifications reported to the Glasgow Medical Officer of Health in 1950–1963. Coloured bands are 95% uncertainty intervals, estimated from a Bayesian negative binomial interrupted time-series regression model. ACF, active case finding; CNR, case notification rate.

Between 1950 and 1956 (pre-ACF period), there was a slow linear decline in pulmonary tuberculosis CNRs overall (equivalent to a 2.3% per year reduction) and in most wards (Fig 1). Wards in the Central and East Districts tended to have higher notification rates than other parts of the city, with some wards showing a flat, or increasing, trend (S6 Fig).

Impact of active case finding campaign on pulmonary tuberculosis notifications

Inspection of trace plots and model diagnostics showed regression models converged well (S7 Fig and S1 Table).

In 1957, when the mass miniature X-ray active case finding intervention was undertaken, there was a doubling in the CNR for Glasgow City as a whole, increasing from 186.8 per 100,000 in 1956 to 363.5 per 100,000 in 1957. In the interrupted time series regression model, comparing 1957 (ACF intervention year) to the counterfactual scenario there was a 1.95-times (95% UI [1.81, 2.11]) increase in the pulmonary tuberculosis CNR across the city (“peak effect”). At the ward level, there were substantial increases in the pulmonary tuberculosis CNR in all wards, with relative rates ranging from 1.73 (95% UI [1.37, 2.06]) in Gorbals to 2.23 (95% UI [1.81, 2.87]) in Camphill (Fig 2).

Fig 2. Impact of mass chest X-ray screening on pulmonary tuberculosis CNRs, overall, and by ward.

Fig 2

(A1) Mean posterior relative pulmonary tuberculosis CNR in 1957 vs. counterfactual (“peak effect”). (A2) Mean posterior relative pulmonary tuberculosis CNR in 1958 vs. counterfactual (“level effect”). (A3) Mean posterior pulmonary tuberculosis relative rate of change in CNRs 1958–1963 vs. counterfactual (“slope effect”). (A2) Ward specific and overall (black) “peak effect,” with 95% uncertainty interval. (B2) Ward specific and overall (black) “level effect,” with 95% uncertainty interval. (A3) Ward specific and overall (black) “slope effect,” with 95% uncertainty interval. UI, uncertainty interval. Ward boundaries obtained from a scale 1951–1952 Post Office Directory map drawn by John Bartholomew FRSG held within the City of Glasgow Archive Special Collections (item PSI-52), digitalised using QGIS 3.34.1.

There was an overall substantial decline in the pulmonary tuberculosis CNR in the year following the ACF intervention (1958). Comparing 1958 to counterfactual trends, we estimate a 35% relative reduction in the Glasgow City case notification rate (relative rate: 0.65, 95% UI [0.59, 0.71]), with consistent effects across wards (Fig 2). There was a positive correlation between the “peak effect” (increase in CNR in 1957 versus counterfactual) and the “level effect” (decrease in CNR in 1958 versus counterfactual), implying that greater increase in case detection in 1957 was associated with a smaller reduction in case notification in the immediate post-ACF year—S8 Fig.

In the post-ACF period (1958 to 1963), the rate of reduction in pulmonary tuberculosis CNRs was greater than in the pre-ACF period. Overall, across Glasgow City during this 6-year period, there was an annual rate of change of −5.4%, compared to −2.3% in the pre-ACF period. All wards had a markedly greater reduction in pulmonary tuberculosis CNRs (“slope effect”) in the post-ACF period compared to the pre-ACF period (Fig 2). There was a positive correlation between greater “peak effect” of ACF, and lower relative reductions in the rate of change post-ACF (“slope effect”). There was no correlation between the “level effect” and the “slope effect”—S8 Fig.

In our extra-pulmonary tuberculosis model, the ACF intervention had little discernible peak (RR: 0.89, 95% UI [0.72, 1.09]), level (RR: 0.85, 95% UI [0.69, 1.03]), or slope effect (RR: 1.13, 95% UI [0.77, 1.60]), either across the city, or at ward level (S9 and S10 Figs).

Estimates of case detection

From our competing hazards model, in the pre-ACF period (1950 to 1956), we estimate that prevalence was <400 per 100,000 in all wards. Assuming a 76% ACF coverage (as estimated from the total number screened and the estimated adult resident population), we estimated ward case detection ratios ranging from 60% to 92%, with a median (IQR) of 78% (72%, 82%). Across wards, we found pre-ACF tuberculosis CNR and case detection ratios were positively correlated (corr = 0.76), and case detection ratios were negatively correlated with ACF impact measured as pre/post notification ratio (corr = −0.55)—S11 Fig.

Cases averted compared to counterfactual scenario

Across the City of Glasgow between 1958 and 1963, we estimate that, compared to the counterfactual scenario where the ACF intervention had not happened, there were 4,599 (95% UI [3,641, 5,683]) pulmonary tuberculosis notifications averted, equivalent to a 42.9% (95% UI [36.9%, 48.7%]) reduction (Table 2).

Table 2. Impact of mass screening intervention in post-ACF period (1958–1963) compared to counterfactual scenario.

Year Difference in case notification rate (per 100,000 py, [95% UI]) Relative case notification rate [95% UI] Tuberculosis notifications averted
[95% UI]
Percentage difference in cases
[95% UI]
PTB 1958 −64.2 [−79.2, −50.1] 0.65 [0.59, 0.71] 675.3 [526.5, 832.8] −35.4% [−41.3%, −29.4%]
PTB 1959 −68.9 [−84.4, −54.6] 0.61 [0.56, 0.67] 723.7 [572.9, 886.1] −38.8% [−44.3%, −32.7%]
PTB 1960 −73.1 [−90.1, −57.9] 0.58 [0.52, 0.64] 759.1 [601.1, 935.1] −41.9% [−47.6%, −36.0%]
PTB 1961 −76.9 [−95.2, −60.2] 0.55 [0.49, 0.61] 789.3 [618.6, 977.6] −44.9% [−50.7%, −38.8%]
PTB 1962 −80.2 [−99.8, −62.2] 0.52 [0.46, 0.59] 817.3 [634.3, 1,017.2] −47.8% [−53.9%, −41.3%]
PTB 1963 −83.1 [−104.3, −63.7] 0.50 [0.43, 0.56] 834.4 [640.3, 1,047.9] −50.4% [−56.9%, −43.5%]
PTB Overall
(1958–1963)
4,599.2 [3,641.4, 5,683.4] −42.9% [−48.7%, −36.9%]
EPTB 1958 −2.3 [−5.5, 0.8] 0.86 [0.70, 1.05] 24.1 [−8.2, 57.4] −13.7% [−30.2%, 5.4%]
EPTB 1959 −1.8 [−4.8, 0.9] 0.88 [0.72, 1.07] 18.9 [−9.1, 50.1] −11.6% [−28.2%, 6.8%]
EPTB 1960 −1.4 [−4.5, 1.3] 0.91 [0.72, 1.12] 14.0 [−13.9, 46.4] −9.3% [−28.1%, 11.8%]
EPTB 1961 −1.0 [−4.3, 2.1] 0.93 [0.70, 1.20] 9.8 [−21.4, 44.2] −6.7% [−29.7%, 20.0%]
EPTB Overall
(1958–1963)
66.8 [−42.7, 192.2] −10.6% [−27.9%, 8.7%]

All estimates are compared to counterfactual scenario where active case finding intervention had not been implemented.

PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; py, person-years.

Impact of active case finding by age group and sex

In the pre-intervention period, there were differences in pulmonary tuberculosis case notification trajectories by age group and sex, with in general declining rates in younger age groups, higher numbers of notifications among older men than women, and older men in particular having an upwards trend in notifications, compared to other groups (S12 Fig). With the intervention, there was a reduction in case notifications in young children (0 to 5 years) (Fig 3). The greatest difference between men and women in cases averted was in older age groups.

Fig 3. Impact of active case finding on case notifications by age group and sex, Glasgow City: 1950–1963.

Fig 3

(A) “Peak effect” on case notifications (1957 vs. counterfactual). (B) “Level effect” on case notifications (1958 vs. counterfactual). (C) “Slope effect” on case notifications (1958–1963 vs. counterfactual). (D) Numbers of pulmonary tuberculosis notifications averted during 1958–1963, compared to counterfactual scenario. UI, uncertainty interval.

Discussion

The Glasgow mass miniature X-ray campaign for tuberculosis in 1957 was probably the largest single community-based active case finding intervention ever undertaken, with more than 715,000 people (622,349 adult Glasgow residents; 76% of the entire adult resident population) screened with miniature chest X-ray over just 5 weeks, equating to nearly 150,000 people screened per week of the campaign. In our analysis using modern epidemiological methods, we found that the mass screening intervention had a substantial immediate impact—doubling case notifications—and resulted in more rapid reductions in the citywide notification rate (5.4% per year) post intervention compared to the pre-intervention period (2.3%), with an estimated 4,599 notified pulmonary tuberculosis case notifications averted between 1958 and 1963 compared to the counterfactual scenario. Consistency in intervention effect across city wards gives confidence that the impact can be attributed to the intervention. By mostly omitting historical evidence of the impact of well-conducted mass X-ray screening programmes in global guideline development and contemporary discourse, it is likely that the potential impact of intensive, high-coverage ACF interventions to change epidemic trajectories has been underestimated.

Neither systematic reviews of historical ACF interventions [14,22,23] nor WHO guidelines for systematic tuberculosis screening [12,13] have included these data from Glasgow in evidence synthesis. A review of historical mass miniature X-ray screening interventions from the 1930s to late 1960s identified 18 published reports from North America, Europe, and India [6]. Synthesising these data Golub and colleagues concluded that mass miniature X-ray screening was highly effective at increasing case detection, particularly when programmes were well supported by community and health system engagement [6]. Likewise, Miller and colleagues emphasised the importance of logistics at large scale to ACF programme success [24]. During the late 1950s however, several large cities in the UK—including Glasgow, Edinburgh, and Liverpool, as well as many cities and countries internationally (Brazil, Japan, Spain, Italy, Sweden) undertook mass miniature X-ray screening for tuberculosis. However, to the best of our knowledge, evidence from these programmes have mostly not been collated, possibly because data reside only in municipal public health reports, rather than in more accessible scientific publications. Moreover, data included in both sets of WHO guidance for community-based systematic screening (2013 [12] and 2021 [13]) include only a small number of historical studies. This represents a missed opportunity: many high tuberculosis burden countries have tuberculosis epidemiological characteristics similar to Europe and North America in the 1950s. By omitting historical evidence, there is a danger that previous lessons learned are forgotten.

Only a small number of contemporary studies have investigated the impact of ACF for tuberculosis on CNRs, with the large majority following up communities only in the period before and during the intervention [14], and with nearly all showing large increases in case detection during implementation. In non-randomised studies, following up communities for prolonged periods after the ACF intervention is critical to identify effects that are temporary or short lived; our analysis here provides compelling evidence that a single intervention with high coverage can change epidemic trajectory. Two contemporary randomised trials of community-based active case finding (ACT3 [15] and TREATS [16]) have shown mixed results on tuberculosis prevalence and infection, with the more intensive ACT3 study in Vietnam resulting in a substantial reduction in prevalent pulmonary tuberculosis following universal sputum testing with Xpert, whereas no effect was identified from the symptom screening approach in TREATS. We speculate that the very high coverage of chest X-ray screening achieved in Glasgow in 1957 was a major contributor to epidemiological impact, and potentially identified people with early and subclinical tuberculosis, rapidly reducing transmission. This would align with the experiences of the ACT3 trial, where universal sputum testing, as in the Glasgow mass screening campaign, likely identified people in the subclinical state [25]. We additionally found that, in the pre-ACF period (1950 to 1956) all Glasgow wards had an estimated tuberculosis prevalence of <400 per 100,000. This is below the current WHO screening threshold of >500 per 100,000 and suggests that epidemiological impact from ACF may be achieved in settings with more concentrated epidemics; this needs confirmation through analysis of a greater number of historical and contemporary data sets. Further research to understand the epidemiological impact of the effect of detection and treatment of early states of tuberculosis is also needed.

Critically important to achieving high population coverage of tuberculosis screening was a programme of mass community engagement and mobilisation, supported by more than 12,000 volunteers. A recent qualitative synthesis of the community views of participating in ACF programmes emphasises that local ownership and leadership, ongoing support for people screened, and health systems strengthening to support the increased healthcare demands generated by mass screening are important determinants of intervention success [26]. The Glasgow mass screening campaign exemplified these principles, and we argue that community and health systems support within contemporary ACF programmes are often insufficient, and delivered in a “top-down”—rather than community-responsive—fashion, likely contributing to lower than anticipated participation and effectiveness.

The postwar period between 1948 and 1960 was a period of tremendous social change, and the 1957 Glasgow mass tuberculosis screening campaign needs to be contextualised alongside progressive improvements in living conditions, nutrition (with the ending of second world war food rationing in 1954), healthcare, and tuberculosis care and prevention. In Glasgow, “slum clearances” commenced in the mid-1950s, particularly in wards in the centre and south of the city such as Camphill, Gorbals, Cowcaddens, and Govan, with new residential schemes established on the peripheries of the city. These changes in ward demographics can be seen in our supplementary figures. However, while the reduction in crowding and removal of dwellings in the worst condition is likely to have beneficial effects for reducing tuberculosis transmission, the slow improvements in social and housing conditions themselves are unlikely to account for the rapid and large changes in tuberculosis notifications that occurred immediately with and in the period after the mass screening campaign.

According to historical Medical Officer of Health reports, Bacillus Calmette–Guérin (BCG) vaccination was first introduced in Glasgow in 1950 and offered to people with a positive tuberculin skin test and in one of the following four categories: “nurses in hospitals, especially institutions for tuberculosis”; “newborn infants of tuberculous mothers”; “contacts of cases of open tuberculosis”; and medical students. In September to November 1953, this BCG vaccination programme was extended to include school children aged 13 years with a positive tuberculin skin test. During the mass screening campaign in 1957, tuberculin skin test positive contacts of participants diagnosed with tuberculosis were additionally offered BCG vaccination. Although systematic reviews suggest that there is evidence to support a protective effect of BCG vaccination on infection and disease, particularly for younger children [27,28], the greatest protective benefit appears to be to infants at risk of severe tuberculosis disease, who themselves are unlikely to transmit to others. Overall, we believe that the Glasgow BCG vaccination programme was unlikely to have been a major contributor to tuberculosis control efforts and is unlikely to explain the substantial increase in the rate of decline of tuberculosis CNRs immediately following the mass screening programme. However, we acknowledge that the combined effects of screening, social improvements, and improved tuberculosis diagnosis and treatment remain difficult to untangle.

We found evidence that the impact of the ACF intervention differed by age group and sex. In young children (<5 years, who themselves were not eligible for screening, although a small number of children <15 years did undergo chest X-ray), CNRs decreased during the intervention year in contrast to other age groups which saw large increases; we speculate that this may indicate evidence of ACF shortening infectious duration and providing early beneficial impact on transmission. For adults, contemporary data from high tuberculosis burden countries show that men have twice the prevalence of undiagnosed pulmonary tuberculosis than women [29]. Men are less likely to participate in prevalence surveys in Africa [30] and Asia [31], and in active case finding trials [15,16,32], prompting calls to target interventions towards men [17]. However, if tuberculosis prevalence was indeed higher in men than women in Glasgow in the 1950s, our analysis suggests that rapid delivery of high coverage of high sensitivity screening (with chest X-ray)—rather than interventions targeted specifically at men—may achieve benefits for all groups, but especially those where disease burden is likely to have been highest. We found no effect on extrapulmonary tuberculosis; this is to be expected, as extrapulmonary tuberculosis notification rates were already low by the time the intervention started, and mass chest X-ray screening targets pulmonary tuberculosis. Importantly, our analysis could only investigate population-level effects on case notifications; previous reviews have emphasised the dearth of information on the individual-level benefits and harms of participating in community tuberculosis screening [33]. There may additionally be important implications for health systems when planning mass screening campaigns. In the Glasgow campaign, additional chest clinics were required to run during weekdays and at weekends to meet demands of new referrals from the screening programme. Although mass tuberculosis screening campaigns may be an opportunity to integrate combined health and public health surveillance interventions (as we have previously argued [17]), programmes need to plan for the substantial additional healthcare resources that will likely be required due to detection of other health issues; in the Glasgow campaign, a substantial burden of non-tuberculosis pulmonary disease was identified requiring assessment at city hospital chest clinics. More recent data from Kenya [34] and South Africa [35] emphasises that in countries undergoing health and demographic transitions, the health needs and prevalence of noncommunicable diseases in people participating in tuberculosis screening programmes continues to be high.

There was little description available of microbiological testing results or treatment outcomes, and it is possible that there was overtreatment of tuberculosis in people screened, or indeed treatment of people with very early subclinical tuberculosis which would not have usually been detected and treated. It is unclear what the implications of potential overtreatment, or indeed treatment of early tuberculosis, would be for participants and health systems. Future ACF trials should systematically record individual- and health systems-benefits and harms of participating in tuberculosis screening programmes, and greater research is needed into the effects of screening and treatment of early tuberculosis disease.

Despite the high-quality data available and the rigorous epidemiological methods used, there are some limitations to this analysis. We assumed a linear trend in tuberculosis CNRs in the pre-ACF period, and projected this forward for the counterfactual scenario in the post-ACF period. It is possible however that—in the absence of the intervention—the rate of decline may have accelerated downwards in the late 1950s to early 1960s, leading us to overestimate impact. We relied on available census data and official ward population estimates from government and municipal sources; however, the population of Glasgow changed rapidly in the late 1950s, and these may have over- or underestimated population denominators, particularly for some wards. We did not have comprehensive data on microbiological results or treatment outcomes for notified cases throughout the study period, nor for participants in the intervention; a post-intervention study of prevalence was not done. Finally, while the rapidity, magnitude, and consistency of impact across wards strongly support a direct causal effect, other factors (“slum clearances,” mobility, general improvements in living conditions, access to healthcare, nutrition, and air quality) may have contributed to improvements in tuberculosis epidemiology.

In conclusion, rapid mass miniature chest X-ray screening of over 715,000 people in Glasgow, Scotland (76% of the entire adult city population within 5 weeks) resulted in an accelerated and sustained reduction in tuberculosis CNRs in Glasgow, with an estimated 4,599 pulmonary tuberculosis case notifications averted in the 6 years following the intervention, and potentially evidence of an intervention effect on reducing transmission to young children. Previous attempts to synthesise data from tuberculosis mass screening programmes have mostly ignored examples from the 1950 to 1960s held in municipal health departments, with the consequence that our understanding of the population benefit of ACF has likely been underestimated. Synthesis and comparative analysis of other historical mass tuberculosis screening programmes could give insights into the magnitude of effectiveness of community-based active case finding programmes. Cities in today’s high tuberculosis burden countries may benefit from mass chest X-ray screening supported by high levels of health system and community engagement, alongside improvements in living conditions.

Supporting information

S1 STROBE Checklist. STROBE statement.

(DOCX)

pmed.1004448.s001.docx (33.8KB, docx)
S1 Table. Summary of posterior draws from pulmonary tuberculosis model.

(CSV)

pmed.1004448.s002.csv (23.5KB, csv)
S1 Text. Additional methods.

(DOCX)

pmed.1004448.s003.docx (27.3KB, docx)
S1 Fig. Divisions and Wards of the City of Glasgow, 1951.

Red box in inset map of Scotland shows location of the main figure (City of Glasgow). Map of Scotland from the UK Office for National Statistics Open Geography Portal (https://geoportal.statistics.gov.uk/datasets/ons::countries-december-2023-boundaries-uk-bfc-2/about), licensed under the Open Government Licence v.3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/). City of Glasgow ward boundaries obtained from a scale 1951–1952 Post Office Directory map drawn by John Bartholomew FRSG held within the City of Glasgow Archive Special Collections (item PSI-52), digitalised using QGIS 3.34.1.

(TIFF)

pmed.1004448.s004.tiff (41.2MB, tiff)
S2 Fig. Glasgow City population by ward.

(TIFF)

pmed.1004448.s005.tiff (43.3MB, tiff)
S3 Fig. Glasgow City population pyramids by year.

(TIFF)

pmed.1004448.s006.tiff (11.6MB, tiff)
S4 Fig. Uptake of tuberculosis screening by age and sex.

(TIFF)

pmed.1004448.s007.tiff (18.8MB, tiff)
S5 Fig. Distribution of pulmonary tuberculosis cases by age group and sex in Glasgow by study period.

ACF: active case finding.

(TIFF)

pmed.1004448.s008.tiff (8.5MB, tiff)
S6 Fig. Pulmonary tuberculosis case notification rates by Glasgow Ward, 1950–1963.

Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

(TIFF)

pmed.1004448.s009.tiff (49.4MB, tiff)
S7 Fig. Rank plots of Markov chain Monte Carlo draws from pulmonary tuberculosis model.

(TIFF)

pmed.1004448.s010.tiff (65.9MB, tiff)
S8 Fig. Posterior distributions of, and correlations between “peak effect,” “level effect,” and “slope effect” of active case finding intervention.

(TIFF)

pmed.1004448.s011.tiff (16.5MB, tiff)
S9 Fig. Impact of active case finding intervention on extra-pulmonary tuberculosis case notification rates, Glasgow City.

Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

(TIFF)

pmed.1004448.s012.tiff (11.6MB, tiff)
S10 Fig. Impact of active case finding intervention on extra-pulmonary tuberculosis case notification rates, ward-level.

Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

(TIFF)

pmed.1004448.s013.tiff (30.9MB, tiff)
S11 Fig. Correlation between estimated case detection active case finding impact.

Points are Ward specific values. CDR: Case detection rate; RR.level: Mean posterior relative pulmonary tuberculosis case notification rate in 1958 vs. counterfactual (“level effect”); Ipre: mean estimated incidence per 100,000 in pre-ACF period; Npre: mean case notification rate per 100,000 in pre-ACF period; prev: estimated prevalence per 100,000 in pre-ACF period (1950–1956); pdens: population density (1,000 people per square kilometre).

(TIFF)

pmed.1004448.s014.tiff (16.5MB, tiff)
S12 Fig. Impact of active case finding intervention on pulmonary tuberculosis by age and sex.

Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

(TIFF)

pmed.1004448.s015.tiff (18.8MB, tiff)

Acknowledgments

We gratefully acknowledge the staff of the Special Collections at the City of Glasgow Archives for facilitating access to historical reports and maps. We also acknowledge Callan T MacPherson and Isabella L MacPherson for assistance in data extraction from historical records.

Abbreviations

ACF

active case finding

BCG

Bacillus Calmette–Guerin

CDR

case detection ratio

CNR

case notification rate

UI

uncertainty interval

Data Availability

Data and code to reproduce analysis are available at https://github.com/petermacp/glasgow-cxr.

Funding Statement

AS and RMGJH were supported by the US National Institutes of Health [grant number R-202309–71190]. HMR was funded by Wellcome [grant number: 225482/Z/22/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58:E9–E12. [PMC free article] [PubMed] [Google Scholar]
  • 2.McKeown T, Record RG. Reasons for the Decline of Mortality in England and Wales during the Nineteenth Century. Popul Stud. 1962;16:94–122. doi: 10.2307/2173119 [DOI] [PubMed] [Google Scholar]
  • 3.Vynnycky E, Fine PEM. The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901. Int J Tuberc Lung Dis. 1997;1:389–396. [PubMed] [Google Scholar]
  • 4.Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol. 2012;10:407–416. doi: 10.1038/nrmicro2797 [DOI] [PubMed] [Google Scholar]
  • 5.Medical Research Council National Tuberculin Survey 1949–1950. Lancet. 1952;259:775–785. doi: 10.1016/S0140-6736(52)91901-6 [DOI] [Google Scholar]
  • 6.Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis. 2005;9:1183–1203. [PMC free article] [PubMed] [Google Scholar]
  • 7.Radiography and Preventing TB on the NHS. In: People’s History of the NHS [Internet]. 13 Dec 2016. [cited 25 Mar 2024]. Available from: https://peopleshistorynhs.org/galleries/radiography-and-preventing-tb-on-the-nhs/. [Google Scholar]
  • 8.McFarlane NM. Tuberculosis in Scotland, 1870–1960. PhD, University of Glasgow. 1990. Available from: https://eleanor.lib.gla.ac.uk/record=b1365269.
  • 9.City of Glasgow. Report of the Medical Officer of Health, Glasgow. Glasgow; 1954. p. 111–112. Available from: https://wellcomecollection.org/works/q2ddam4b/items.
  • 10.WHO Expert Committee on Tuberculosis. Ninth report. World Health Organ Tech Rep Ser. 1974;1–40. [PubMed]
  • 11.World Health Organization. Global Tuberculosis Report. Geneva; 2023. Available from: https://www.who.int/publications/i/item/9789240083851.
  • 12.World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. 2013. Available from: https://www.who.int/tb/tbscreening/en/. [PubMed] [Google Scholar]
  • 13.World Health Organization. WHO consolidated guidelines on tuberculosis. Model 2: screening. Systematic screening for tuberculosis disease. Geneva; 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/340255/9789240022676-eng.pdf. [PubMed]
  • 14.Burke RM, Nliwasa M, Feasey HRA, Chaisson LH, Golub JE, Naufal F, et al. Community-based active case-finding interventions for tuberculosis: a systematic review. Lancet Public Health. 2021;0. doi: 10.1016/S2468-2667(21)00033-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Marks GB, Nguyen NV, Nguyen PTB, Nguyen T-A, Nguyen HB, Tran KH, et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med. 2019;381:1347–1357. doi: 10.1056/NEJMoa1902129 [DOI] [PubMed] [Google Scholar]
  • 16.Klinkenberg E, Floyd S, Shanaube K, Mureithi L, Gachie T, de Haas P, et al. Tuberculosis prevalence after 4 years of population-wide systematic TB symptom screening and universal testing and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: A cross-sectional survey (TREATS). PLoS Med. 2023;20:e1004278. doi: 10.1371/journal.pmed.1004278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.MacPherson P, Shaunabe K, Phiri MD, Rickman HM, Horton KC, Feasey HRA, et al. Community-based active-case finding for tuberculosis: navigating a complex minefield. BMC Global Public Health. 2024;2:9. doi: 10.1186/s44263-024-00042-9 [DOI] [Google Scholar]
  • 18.Cowan K Sir. Glasgow’s X-ray campaign against tuberculosis 11th March-12th April, 1957. Glasgow: Printed by Glasgow Corporation Printing and Stationery Department; 1957. Available from: https://go.exlibris.link/6SMMP9kp. [Google Scholar]
  • 19.Wellcome. The Medical Officer of Health reports. [cited 2024 Mar 25]. Available from: https://wellcomelibrary.org/moh/about-the-reports/about-the-medical-officer-of-health-reports/.
  • 20.Bürkner P-C. brms: An R Package for Bayesian Multilevel Models Using Stan. J Stat Softw. 2017;80:1–28. doi: 10.18637/jss.v080.i01 [DOI] [Google Scholar]
  • 21.Tiemersma EW, Werf MJ van der, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review. PLoS ONE. 2011;6:e17601. doi: 10.1371/journal.pone.0017601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kranzer K, Afnan-Holmes H, Tomlin K, Golub JE, Shapiro AE, Schaap A, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis. 2013;17:432–446. doi: 10.5588/ijtld.12.0743 [DOI] [PubMed] [Google Scholar]
  • 23.Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increase tuberculosis case detection at primary healthcare or community-level services. Cochrane Database Syst Rev. 2017. [cited 2024 Mar 25]. doi: 10.1002/14651858.CD011432.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Miller C, Lonnroth K, Sotgiu G, Migliori GB. The long and winding road of chest radiography for tuberculosis detection. Eur Respir J. 2017:49. doi: 10.1183/13993003.00364-2017 [DOI] [PubMed] [Google Scholar]
  • 25.Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M, et al. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med. 2024;S2213-2600(24):00028–00026. doi: 10.1016/S2213-2600(24)00028-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Taylor M, Medley N, van Wyk SS, Oliver S. Community views on active case finding for tuberculosis in low- and middle-income countries: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2024. [cited 2024 Mar 26]. doi: 10.1002/14651858.CD014756.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470–480. doi: 10.1093/cid/cit790 [DOI] [PubMed] [Google Scholar]
  • 28.Martinez L, Cords O, Liu Q, Acuna-Villaorduna C, Bonnet M, Fox GJ, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health. 2022;10:e1307–e1316. doi: 10.1016/S2214-109X(22)00283-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. PLoS Med. 2016;13:e1002119. doi: 10.1371/journal.pmed.1002119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Law I, Floyd K, African TB Prevalence Survey Group. National tuberculosis prevalence surveys in Africa, 2008–2016: an overview of results and lessons learned. Trop Med Int Health. 2020;25:1308–1327. doi: 10.1111/tmi.13485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K. National tuberculosis prevalence surveys in Asia, 1990–2012: an overview of results and lessons learned. Trop Med Int Health. 2015;20:1128–1145. doi: 10.1111/tmi.12534 [DOI] [PubMed] [Google Scholar]
  • 32.Feasey HRA, Khundi M, Soko RN, Bottomly C, Chiume L, Burchett HE, et al. Impact of active case-finding for tuberculosis on case-notifications in Blantyre, Malawi: a community-based cluster-randomised trial (SCALE). PLoS Glob Public Health. (In press). doi: 10.1371/journal.pgph.0002683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Telisinghe L, Ruperez M, Amofa-Sekyi M, Mwenge L, Mainga T, Kumar R, et al. Does tuberculosis screening improve individual outcomes? A systematic review. EClinicalMedicine. 2021;40:101127. doi: 10.1016/j.eclinm.2021.101127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mungai BN, Joekes E, Masini E, Obasi A, Manduku V, Mugi B, et al. ‘If not TB, what could it be?’ Chest X-ray findings from the 2016 Kenya Tuberculosis Prevalence Survey. Thorax. 2021;76:607–614. doi: 10.1136/thoraxjnl-2020-216123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wong EB, Olivier S, Gunda R, Koole O, Surujdeen A, Gareta D, et al. Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob Health. 2021;9:e967–e976. doi: 10.1016/S2214-109X(21)00176-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Katrien G Janin

22 Jul 2024

Dear Dr MacPherson,

Thank you for submitting your manuscript entitled "Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950-1963: an epidemiological analysis of historical data" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Jul 24 2024 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email me at kjanin@plos.org if you have any queries relating to your submission.

Kind regards,

Katrien G. Janin, PhD

Senior Editor

PLOS Medicine

Decision Letter 1

Katrien G Janin

29 Aug 2024

Dear Dr MacPherson,

Many thanks for submitting your manuscript "Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950-1963: an epidemiological analysis of historical data" (PMEDICINE-D-24-02288R1) to PLOS Medicine. The paper has been reviewed by subject experts and a statistician; their comments are included below and can also be accessed here: [LINK]

As you will see, the reviewers [ADD DETAILS AS APPROPRIATE]. After discussing the paper with the editorial team and an academic editor with relevant expertise, I'm pleased to invite you to revise the paper in response to the reviewers' comments. We plan to send the revised paper to some or all of the original reviewers, and we cannot provide any guarantees at this stage regarding publication.

When you upload your revision, please include a point-by-point response that addresses all of the reviewer and editorial points, indicating the changes made in the manuscript and either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please also be sure to check the general editorial comments at the end of this letter and include these in your point-by-point response. When you resubmit your paper, please include a clean version of the paper as the main article file and a version with changes tracked as a marked-up manuscript. It may also be helpful to check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper.

We ask that you submit your revision by Sep 19 2024 11:59PM. However, if this deadline is not feasible, please contact me by email, and we can discuss a suitable alternative.

Don't hesitate to contact me directly with any questions (kjanin@plos.org).

Best regards,

Katrien

Katrien Janin, PhD

Associate Editor

PLOS Medicine

kjanin@plos.org

-----------------------------------------------------------

Comments from the academic editor:

Thanks for this interesting article. We would need the authors to temper the language a bit though, although epidemiologically the inidence rates are similar in some LMIC now to where Scotland was in the 50s, the diagnostics used in ACF and (treatment available) is very different. So the generalisability will be fairly limited.

-----------------------------------------------------------

Editorial comment:

On the practices of the times, we wondered how the BCG vaccination may have played a role. If online sources are to be believed, the vaccination program started in 1953 and we wondered if (and how) this may have an impact.

-----------------------------------------------------------

Comments from the reviewers:

Reviewer #1: Thank you for the excellent work.

The topic, methodology and outcome from your study will have relevance to many high burden settings.

This work presents the opportunity to inform policy while built on the usage of existing data.

Active case finding for TB and the use of CXRs are a very important topic as we try and address the substantial burden of undiagnosed TB.

Comments:

Line 123-126: Great to include details on the incentives used in the implementation. Line 405: you do speculate around the role of the high coverage of the screening

It may be worthwhile revisiting this in the discussion with some consideration of what it may take to achieve similar in our current context. The use of incentives in trials has substantial oversight from ethics committees and it is near impossible for me to conceive that an existing Ministry of Health in a high burden setting would be able to budget and implement such an incentive programme.

In addition, the irony of cigarette incentives for a chest x ray screening programme warrants some consideration of the evolution in Public Health approach that the world has seen in the last 70 years.

Line 253-254: This nicely points to potential value of CXR screening beyond TB. It is understandable that more detailed analysis of this is outside of the scope of your article, but a comment in the discussion on this would be very useful. As high burden countries in resource limited settings need to consider costs and benefits, the utliity of this programme beyond TB could further support implementation. Perhaps reference to any other work that has projected the additional benefits and opportunities to integrate with more holisitic health screening or the need for future analyses that explore this would be good

During the ACF intervention - Glasgow almost doubled its case notification in that 1 year. While you have stated you were unable to track and report outcomes, it is essential to describe and consider the ability of a City to effectively deal with a doubling in case notification. In the conclusion you describe the support needed for the implementation of the CXR screening but weak/fragile health systems could be especially vulnerable to a surge in TB diagnoses. Could you consider describing what Glasgow had in place to manage this increase or what a high-burden, resource limited setting may want to put in place to ensure optimum treatment outcomes

Minor comments

Line 55-56: Consider changing to month by name as per main text to eliminate confusion with ddmmyyyy and mmddyyyy

Line 389: American should be America

Line 389: missing is .....evidence, there is a danger.........

line 471: delete of

Thank you

Reviewer #2: This represents a key addition to the historical evidence base that community-wide systematic screening.

Crucially, current WHO TB screening recommendation offer only a conditional recommendation, when prevalence is 0.5% or greater. I totally concur with the premise of the paper, that the historical evidence in general has been insufficiently evaluated to inform current screening recommendations and practices.

This paper documents a historical experience where prevalence was demonstrably less than that threshold, and documents the efforts and impact of a single campaign intervention fairly exhaustively.

It represents a remarkable contribution to the historical evidence base, complements the re-analysis from Kolin that many of the authors have participated in previously, and demonstrates that an analysis 50 years late is still better late than never.

My first reaction was to just accept the paper. But a few nagging issues have made me change to minor revision. There are some unanswered questions, which I would encourage the authors to explore.

major issue 1: The issue of poor bacteriological confirmation during the screening and the lack of a sub-analysis around microbiologically confirmed cases.

This depends on the quality of bacteriology available during the day, and it's utilization, which is not quite addressed.

The paper mentions practices, "where there was "significant radiological abnormality requiring further investigation or supervision",

132 people were recalled for a large film at a central X-ray site, and assessment/further investigation

133 by physicians at five city hospitals chest clinics (one per Division, including microbiological

134 testing of sputum) and tuberculosis treatment (if required).

What does that microbiological examination consist of? Is there data?

We are told that "A total of 30,506 people

241 (4.3% of all X-rayed) were recalled for full film, with 652, (2.1%) not attending; 13,900 (45.6%)

242 were subsequently assessed at chest clinics.

Later we are told that in the screening program

2,369/622,349 (0.4%) Glasgow resident cases detected; approximately

245 65% were treated as outpatients. A further 1,556 people of all ages were notified with

246 tuberculosis through routine systems during 1957, meaning that the ACF campaign accounted

247 for 60% of all notifications in that year. Of the 2,369 adult Glasgow residents diagnosed with

248 tuberculosis due to screening, 58.5% (1,387) were male, and prevalence was highest in older

249 age groups; 523 (22%) were bacteriologically-confirmed by isolation of M. tuberculosis.

\\With only 22% of detected cases that were bacteriologically confirmed, one wonders, what exactly was being detected and treated? Amongst these 13,900 detected by the screening program and referred to chest clinics with full radiographs, 4 in 5 were unable to be bacteriologically confirmed, by the

How important, or not important these individuals were to the subsequent impact observed remains untold, and indeed unexplored. Because there were still 1,556 persons routinely diagnosed during the year, presumably because they were sick. One could argue that it doesn't matter, because the screening program happened, they detected and treated these cases, and that was the impact. But because the intervention was mass radiographic screening, involving 37 units and 12,000 volunteers and a whole of society campaign for a paltry 1 million population (one unit and ~300 volunteers for every ~25K population), it does matter. Was the additional impact that is shown very convincingly being driven by the 523 who were (presumably) smear or culture positive, vs the (2369-523=)1846 who were apparently bacteriologically negative? Was the reduction in level and slope of notification a direct effect of removing prevalent TB cases and their subsequent transmission, or was it an effect of 'treatment as prevention' to radiographic abnormals, effectively pre-treated a subset of future cases in the campaign year? Was the effect due to reduced transmission, or due to mass prophylactic treatment to a thousands of high risk individuals?

Accordingly I'd recommend (a) the notification table 1 (routine and screening) be updated and split by bacteriologic confirmation (or an additional main table added with the stratification - not the supplement, please). (b) a sub-analysis accounting for the pre and post screening impact on bacteriologically confirmed TB be conducted. I don't know if it will have the power to detect. This recommendation is contingent on the bacteriological practices of the day. If the bacteriological confirmation was done by smear only, then this is probably not worth it to do the subanalysis due to insensitivity of detection, and would just add the caveat around bacteriologic confirmation as a limitation in the discussion.

There's some reference in the discussion that this might not have been possible.

"There was little description available of microbiological

454 testing results or treatment outcomes, and it is possible that there was over-treatment of

455 tuberculosis in people screened, or indeed treatment of people with very early subclinical TB

456 which would not have usually been detected and treated. "

However, I'd suggest that this be included in the methods up front and at least better discussion of what it was that actually might have been driving change.

Minor issue 1:

"However, uptake of screening was low in these two trials, with only 45% of eligible

404 participants screened by sputum Xpert in the best performing year of ACT3. We speculate that

405 the very high coverage of chest X-ray screening achieved in Glasgow in 1957 was a major

406 contributor to epidemiological impact, and potentially identified people with early and

407 subclinical tuberculosis, rapidly reducing transmission."

I have some issue with this interpretation. In ACT3, nearly 80% of the ennumerated population was reached, but specimens were only successfully collected and tested from 45%. To declare that this was low coverage and that's the possible difference is to infer that the prevalence of disease was similar amongst those reached who could not produce a sputum vs those who were able to produce a sputum. That is not consistent with data from prevalence surveys. Also ACT3 had very minimal criteria to reject a sputum, basically volume based. Also ACT3 had a relatively large impact by the metrics provided. So the representation of ACT3, and the point being made about it, doesn't make sense. I think you're trying to say that the effect of ACT3 was actually similar of that observed here, and those differences are interesting and should be explored. On one hand you have a lower sensitivity screening tool (MMR, which is lower than current dCXR can detect), on the other you have molecular testing irrespective of CXR results, including detection of some individuals who may have not had detectable CXR abnormalities.

So it's apples and oranges, and I think maybe a bit more nuance about the comparison is warranted.

Minor issue 2:

Discussion - context needed about secular trends, with more information and a bit more humility in attribution of the changes occurring to the screening campaign.

There's no mention of a rather momentous event of the time, which is the post-war lifting of food rations in 1954 in England, or the effect of improved nutritional conditions.

That may have had some interaction with the accelerated decline in rates. Which speaks to the question, this was a singled-ended one time event Glasgow. What about places which didn't have such a massive screening campaign, and had to exist with the secular changes of the time? A more thorough evaluation would at least acknowledge this limitation.

It's mentioned in the limitation:

"It is possible however that - in the absence of the intervention -

463 the rate of decline may have accelerated downwards in the late 1950s to early 1960s, leading us

464 to over-estimate impact."

However, why not actually go farther and propose a more detailed evaluation of the historical evidence of the day, then, comparing other areas? There's a grad student in there, looking for a PhD topic...

Minor issue 3:

"435 We found strong evidence that the impact of the ACF intervention diYered by age group and sex.

436 In young children (<5 years, who themselves weren't eligible for screening, although a small

437 number of children <15 years did undergo chest X-ray), case notification rates decreased during

438 the intervention year in contrast to other age groups which saw large increases; we speculate

439 that this may indicate evidence of ACF shortening infectious duration and providing early

440 beneficial impact on transmission."

This is a bit hard to swallow from the data presented, which appear to have been drawn from very small numbers, for the young children argument. the numbers averted suggested that the rate change was applied to a very small number of cases both before and after the intervention. Perhaps please provide the numbers of notification, and the rate among kids, in the pre and post period. Birth rates may have also been expanding in the postwar era, inflating the infant denominator.

Perhaps this also needs to be couched with the unmentioned counterpoint, that there was an increase in slope of notifications in the 6-15 age group. So it's not really clear what's 'strong' evidence here. Possible evidence, maybe.

The conclusion paragraph seems to acknowledge this and pull back. "479 and potentially evidence of an intervention eYect on reducing transmission to young children."

Minor issue 4:

"475 In conclusion, rapid mass miniature chest X-ray screening of over 715,000 people in Glasgow,

476 Scotland (76% of the entire adult city population within 5 weeks) resulted in an accelerated and

477 sustained reduction in tuberculosis case notification rates in Glasgow, with an estimated 4,656

478 pulmonary tuberculosis case notifications averted in the six years following the intervention,

479 and potentially evidence of an intervention eYect on reducing transmission to young children."

This conclusion may need to be couched in less certain causality, given the uncertainties in secular trends. It's likely to have resulted.

Lastly I want to thank the authors for taking this analysis on, and for the scholarship involved to recover this learning opportunity from the dustbin of history. It's relevant and important, and PlosMED should publish it ASAP.

Puneet Dewan, BMGF

Reference: https://assets.publishing.service.gov.uk/media/5a81669340f0b62305b8ebfc/Domestic_Food_Consumption_and_Expenditure_1956.pdf

Reviewer #3: See attachment

Michael Dewey

Any attachments provided with reviews can be seen via the following link: [LINK]

--------------------------------------------------------- ---

General editorial requests:

(Note: not all will apply to your paper, but please check each item carefully)

* We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. Please do not add or remove authors without first discussing this with the handling editor. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

* Please upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

* Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information (web or email address) for obtaining the data. Please note that a study author cannot be the contact person for the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

* We expect all researchers with submissions to PLOS in which author-generated code underpins the findings in the manuscript to make all author-generated code available without restrictions upon publication of the work. In cases where code is central to the manuscript, we may require the code to be made available as a condition of publication. Authors are responsible for ensuring that the code is reusable and well documented. Please make any custom code available, either as part of your data deposition or as a supplementary file. Please add a sentence to your data availability statement regarding any code used in the study, e.g. "The code used in the analysis is available from Github [URL] and archived in Zenodo [DOI link]" Please review our guidelines at https://journals.plos.org/plosmedicine/s/materials-software-and-code-sharing and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. Because Github depositions can be readily changed or deleted, we encourage you to make a permanent DOI'd copy (e.g. in Zenodo) and provide the URL.

FORMATTING - GENERAL

* Abstract: Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions). Please combine the Methods and Findings sections into one section. In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.

* At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Ideally each sub-heading should contain 2-3 single sentence, concise bullet points containing the most salient points from your study. In the final bullet point of 'What Do These Findings Mean?', please include the main limitations of the study in non-technical language. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary.

* Please express the main results with 95% CIs as well as p values. When reporting p values please report as p<0.001 and where higher as the exact p value p=0.002, for example. Throughout, suggest reporting statistical information as follows to improve clarity for the reader "22% (95% CI [13%,28%]; p</=)". Please be sure to define all numerical values at first use.

* Please include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not restart the numbering on each page).

* Please cite the reference numbers in square brackets. Citations should precede punctuation.

FIGURES AND TABLES

* Please provide titles and legends for all figures and tables (including those in Supporting Information files).

* Please define all abbreviations used in each figure/table (including those in Supporting Information files).

* Please consider avoiding the use of red and green in order to make your figure more accessible to those with color blindness.

SUPPLEMENTARY MATERIAL

* Please note that supplementary material will be posted as supplied by the authors. Therefore, please amend it according to the relevant comments outlined here.

* Please cite your Supporting Information as outlined here: https://journals.plos.org/plosmedicine/s/supporting-information

REFERENCES

* PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

* Please ensure that journal name abbreviations match those found in the National Center for Biotechnology Information (NCBI) databases (http://www.ncbi.nlm.nih.gov/nlmcatalog/journals), and are appropriately formatted and capitalised.

* Where website addresses are cited, please include the complete URL and specify the date of access (e.g. [accessed: 12/06/2023]).

* Please also see https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references for further details on reference formatting.

Attachment

Submitted filename: macpherson.pdf

pmed.1004448.s016.pdf (99.3KB, pdf)

Decision Letter 2

Heather Van Epps

29 Sep 2024

Dear Dr. MacPherson,

Many thanks for submitting your revised manuscript "Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950-1963: an epidemiological analysis of historical data" (PMEDICINE-D-24-02288R2) to PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor, and it was also seen again by the statistical reviewer. I am pleased to say that we were all pleased with the edits to the manuscript and the additional discussion and historical context that was added. As such, we plan to accept the paper for publication in the journal, pending attention to a few remaining editorial and production issues.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen here: [LINK]

As a reminder, we ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

We expect to receive your revised manuscript within 1 week (Oct 7th). If this deadline does not seem feasible, or you have any questions, please email me directly at hvanepps@plos.org. Otherwise, I look forward to receiving the final revision.

Kind regards,

Heather

Heather Van Epps, PhD

Executive Editor

PLOS Medicine

hvanepps@plos.org

------------------------------------------------------------

Requests from Editors:

1. Author summary: Please consider revising the third bullet point in the ‘What did the authors do and find’ section as follows (adding ‘rates’ before ‘doubled’ and adding a comma after ‘Post-intervention’: “Before the mass screening intervention (1950-1956), tuberculosis notification rates were declining at 2.3% per year, and rates doubled in the year of the intervention (1957). Post-intervention, tuberculosis notification rates declined at 5.4% per year, and there were an estimated 4,599 pulmonary notifications averted.”

2. Please ensure that the study is reported according to the STROBE (or appropriate STOBE extension) guideline (available from: https://www.equator-network.org/reporting-guidelines/strobe) and include the completed STROBE (or STROBE extension) checklist as Supporting Information. Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist)." When completing the checklist, please use section and paragraph numbers, rather than page numbers.

3. To help us extend the reach of your research, please provide any X (formerly known as Twitter) handle(s) that would be appropriate to tag, including your own, your co-authors’, your institution, funder, or lab. Please enter in the submission form any handles you wish to be included when we post about this paper.

Comments from Reviewers:

Reviewer #3:

The authors have addressed my points. Our remaining differences are very minor and I would not want to push them.

Michael Dewey

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Heather Van Epps

3 Oct 2024

Dear Dr MacPherson, 

On behalf of my colleagues and the Academic Editor, Amitabh Bipin Suthar, I am pleased to inform you that we have agreed to publish your manuscript "Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950-1963: an epidemiological analysis of historical data" (PMEDICINE-D-24-02288R3) in PLOS Medicine.

I appreciate your thorough responses to the final editorial comments. We look forward to publishing your manuscript, and there is only one small point to address prior to publication. We ask that you please add line numbers to your STROBE checklist and submit an updated version. If you have any questions or concerns at any stage of the post-accept process, please feel free to contact me at hvanepps@plos.org.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Kind regards,

Heather

Heather Van Epps, PhD 

Executive Editor 

PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 STROBE Checklist. STROBE statement.

    (DOCX)

    pmed.1004448.s001.docx (33.8KB, docx)
    S1 Table. Summary of posterior draws from pulmonary tuberculosis model.

    (CSV)

    pmed.1004448.s002.csv (23.5KB, csv)
    S1 Text. Additional methods.

    (DOCX)

    pmed.1004448.s003.docx (27.3KB, docx)
    S1 Fig. Divisions and Wards of the City of Glasgow, 1951.

    Red box in inset map of Scotland shows location of the main figure (City of Glasgow). Map of Scotland from the UK Office for National Statistics Open Geography Portal (https://geoportal.statistics.gov.uk/datasets/ons::countries-december-2023-boundaries-uk-bfc-2/about), licensed under the Open Government Licence v.3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/). City of Glasgow ward boundaries obtained from a scale 1951–1952 Post Office Directory map drawn by John Bartholomew FRSG held within the City of Glasgow Archive Special Collections (item PSI-52), digitalised using QGIS 3.34.1.

    (TIFF)

    pmed.1004448.s004.tiff (41.2MB, tiff)
    S2 Fig. Glasgow City population by ward.

    (TIFF)

    pmed.1004448.s005.tiff (43.3MB, tiff)
    S3 Fig. Glasgow City population pyramids by year.

    (TIFF)

    pmed.1004448.s006.tiff (11.6MB, tiff)
    S4 Fig. Uptake of tuberculosis screening by age and sex.

    (TIFF)

    pmed.1004448.s007.tiff (18.8MB, tiff)
    S5 Fig. Distribution of pulmonary tuberculosis cases by age group and sex in Glasgow by study period.

    ACF: active case finding.

    (TIFF)

    pmed.1004448.s008.tiff (8.5MB, tiff)
    S6 Fig. Pulmonary tuberculosis case notification rates by Glasgow Ward, 1950–1963.

    Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

    (TIFF)

    pmed.1004448.s009.tiff (49.4MB, tiff)
    S7 Fig. Rank plots of Markov chain Monte Carlo draws from pulmonary tuberculosis model.

    (TIFF)

    pmed.1004448.s010.tiff (65.9MB, tiff)
    S8 Fig. Posterior distributions of, and correlations between “peak effect,” “level effect,” and “slope effect” of active case finding intervention.

    (TIFF)

    pmed.1004448.s011.tiff (16.5MB, tiff)
    S9 Fig. Impact of active case finding intervention on extra-pulmonary tuberculosis case notification rates, Glasgow City.

    Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

    (TIFF)

    pmed.1004448.s012.tiff (11.6MB, tiff)
    S10 Fig. Impact of active case finding intervention on extra-pulmonary tuberculosis case notification rates, ward-level.

    Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

    (TIFF)

    pmed.1004448.s013.tiff (30.9MB, tiff)
    S11 Fig. Correlation between estimated case detection active case finding impact.

    Points are Ward specific values. CDR: Case detection rate; RR.level: Mean posterior relative pulmonary tuberculosis case notification rate in 1958 vs. counterfactual (“level effect”); Ipre: mean estimated incidence per 100,000 in pre-ACF period; Npre: mean case notification rate per 100,000 in pre-ACF period; prev: estimated prevalence per 100,000 in pre-ACF period (1950–1956); pdens: population density (1,000 people per square kilometre).

    (TIFF)

    pmed.1004448.s014.tiff (16.5MB, tiff)
    S12 Fig. Impact of active case finding intervention on pulmonary tuberculosis by age and sex.

    Empirical and modelled case notification rates (per 100,000 population) by ward, with counterfactual of no active case finding intervention. The mass miniature X-ray active case finding campaign occurred between dashed lines (11th March–12th April 1957). CNR: case notification rate. ACF: active case finding.

    (TIFF)

    pmed.1004448.s015.tiff (18.8MB, tiff)
    Attachment

    Submitted filename: macpherson.pdf

    pmed.1004448.s016.pdf (99.3KB, pdf)
    Attachment

    Submitted filename: 2024-08-30_glasgow-acf_r1_response.pdf

    pmed.1004448.s017.pdf (203.5KB, pdf)
    Attachment

    Submitted filename: 2024-09-30_glasgow-acf_r3_response.docx

    pmed.1004448.s018.docx (33.4KB, docx)

    Data Availability Statement

    Data and code to reproduce analysis are available at https://github.com/petermacp/glasgow-cxr.


    Articles from PLOS Medicine are provided here courtesy of PLOS

    RESOURCES